Aurobindo Pharma announced Q1FY23 results: Revenue from Operations at Rs 6,235.9 crore increased by 9.4% YoY US formulations revenue increased by 10.8% YoY to Rs 2,971.1 crore Europe formulation revenue stood at Rs 1,548.1 crore, with decrease of 2.2% YoY mainly due to Euro currency depreciation Growth Markets grew by 30.8% YoY to Rs 430.6 crore ARV revenue improved by 28.1% YoY to Rs 379.6 crore API revenue increased by 11.6% YoY to Rs 906.5 crore EBIDTA before Forex and Other income stood at Rs 964.7 crore; EBITDA margin for the quarter was 15.5% Research & Development (R&D;) spend at Rs 310 crore, 5.0 % of revenues (Q1 FY22: 6.3%) Received final approval for 10 ANDAs including 4 injectable products from the USFDA Net Profit stood at INR 520.5 crore as against Rs 576.4 crore in the previous quarter Basic & Diluted EPS is Rs 8.88 per share Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We delivered a good performance amidst challenging environment, while reinforcing our growth pillars. Investments in product portfolio continued at a healthy pace as reflected in the filings and launches in the quarter. Our focus on the development of specialty products pipeline will establish new avenues to grow the business in future. This along with our aim to drive sustained improvement in profitability through newer avenues will enhance improved profitability over medium to long term.” Result PDF